口内乾燥症(口渇)治療薬の世界市場2020-2025

◆英語タイトル:Xerostomia (Dry Mouth Disease) Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)
◆商品コード:MOR2011249
◆発行会社(リサーチ会社):Mordor Intelligence
◆発行日:2020年8月
◆ページ数:124
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名利用)USD4,250 ⇒換算¥484,500見積依頼/購入/質問フォーム
Team User(5名利用)USD4,750 ⇒換算¥541,500見積依頼/購入/質問フォーム
Corporate License(法人利用)USD6,000 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMordor Intelligence社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Mordor Intelligence社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、口内乾燥症(口渇)治療薬の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別(人工唾液/唾液代替物、唾液刺激剤)分析、製品別(薬物、唾液ペン、その他)分析、流通チャンネル別(病院薬局、小売り薬局、オンライン薬局)分析、地域別分析、競争状況、市場機会・将来動向などを整理しました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・口内乾燥症(口渇)治療薬の世界市場規模:種類別(人工唾液/唾液代替物、唾液刺激剤)
・口内乾燥症(口渇)治療薬の世界市場規模:製品別(薬物、唾液ペン、その他)
・口内乾燥症(口渇)治療薬の世界市場規模:流通チャンネル別(病院薬局、小売り薬局、オンライン薬局)
・口内乾燥症(口渇)治療薬の世界市場規模:地域別
・競争状況
・市場機会・将来動向
【レポートの概要】

Xerostomia, commonly referred to as dry mouth syndrome, is a result of reduced or absent salivary flow producing mucosal dryness. The increase in radiation therapy and chemotherapy is likely to lead to an increased incidence of xerostomia, which is estimated to predominantly drive the xerostomia therapeutics market. Other factors driving the market growth include increasing usage of prescription medicines, easy availability and cost-effectiveness of medicines, growing geriatric population base and increasing prevalence of diseases, such as Sjogren’s syndrome, HIV, diabetes, and Alzheimer’s disease, among other diseases. Moreover, factors, such as lack of awareness and unavailability of effective treatment, is likely to hinder the usage of xerostomia therapeutics products and can act as a restraining factor for the xerostomia therapeutics market.

[Key Market Trends]
Artificial Saliva/Saliva Substitutes Segment Expected to Dominate the Market Over the Forecast Period
The reduction of saliva in the mouth can lead to tooth decay, mouth infections, an altered sense of taste or smell, difficulty in swallowing, pain, and many other complications. Artificial saliva is a liquid or aerosol product that is sprayed into the mouth. They are designed to moisten and relieve the pain and discomfort from chronic dry mouth, especially with regular use. Many artificial saliva sprays and gels claim to work for up to two hours, and many users require more frequent applications to maintain moisture in the mouth, which can greatly interfere with a good night’s sleep and daily activity. Several saliva sprays and gels also have a reputation for strong and unpleasant flavors, though a recent increase in the use of naturally sweet xylitol has led to the availability of better alternatives. Hence, owing to the aforementioned factors, along with rising disease burden, and availability of over-the-counter artificial saliva products, the segment is expected to register a steady growth during the forecast period.

[Asia-Pacific is Expected to be the Fastest Growing Region Over the Forecast Period]
The Asia-Pacific region is expected to register a lucrative CAGR over the forecast period due to factors, such as growing healthcare expenditure, an increase in initiatives for raising awareness, and rising prevalence of diseases, such as diabetes, HIV, cancer, and Parkinson’s disease that cause dry mouth conditions. Cancer rates are increasing drastically in the Asia-Pacific region. Owing to rising incomes and better access to childhood vaccinations, the life expectancy in the region is high, which increases health risks related to behavioral factors, in turn resulting in cancer. Emerging economies, such as China and India, have adopted both health and industrial policy for encouraging domestic production of cancer drugs, which is leading to lower therapy costs. Lower therapy costs, coupled with increasing awareness about cancer, is leading to higher adoption of chemotherapy and radiotherapy.

[Competitive Landscape]
Key players in xerostomia (dry mouth disease) therapeutics market are focusing on the development of their product portfolio, acquisition of emerging players, and distribution agreements to increase their geographical presence. In May 2018: Prisyna, the oral care division of Synedgen, received 510(k) clearance from the US Food and Drug Administration (FDA) to market its family of Moisyn products designed to treat xerostomia. Some of the key players dominating the xerostomia therapeutics market are 3M, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin, Parnell Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd, and Synedgen, among others.

[Reasons to Purchase this report]
• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

【レポートの目次】

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population
4.2.2 Increasing Adoption of Chemotherapy and Radiotherapy in Cancer Treatment
4.2.3 Rising Burden of Diseases, such as Sjogren’s Syndrome, HIV, Diabetes, Alzheimer’s disease, and Other Diseases
4.3 Market Restraints
4.3.1 Lack of Awareness of Xerostomia in Developing and Underdeveloped Economies
4.3.2 Unavailability of Effective Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Artificial Saliva/Saliva Substitutes
5.1.2 Salivary Stimulants
5.2 By Product
5.2.1 Drugs
5.2.2 Salivary Pens
5.2.3 Other Product Types
5.3 By Distribution Channel
5.3.1 Hospital Pharmacy
5.3.2 Retail Pharmacy
5.3.3 Online Pharmacy
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Quest Products Inc.
6.1.2 Fresenius SE & Co. KGaA
6.1.3 GlaxoSmithKline PLC
6.1.4 Hikma Pharmaceuticals PLC
6.1.5 Lupin Limited
6.1.6 Pharmascience Inc (Pendopharm)
6.1.7 Parnell Pharmaceuticals Inc.
6.1.8 Bausch Health Companies Inc.
6.1.9 Sun Pharmaceutical Industries Ltd
6.1.10 Synedgen Inc. (Prisyna)
6.1.11 ADVANZ PHARMA Corp. Limited
6.1.12 Saliwell Ltd
6.1.13 3M company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[口内乾燥症(口渇)治療薬の世界市場2020-2025]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆